Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.
about
Can molecular imaging enable personalized diagnostics? An example using magnetomotive photoacoustic imaging.Cyclooxgenase-2 inhibiting perfluoropoly (ethylene glycol) ether theranostic nanoemulsions-in vitro studyPerfluorocarbon nanoparticles for physiological and molecular imaging and therapyPerfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent.Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer.Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsionsPhase-shift, stimuli-responsive drug carriers for targeted delivery.Multimodality cardiovascular molecular imaging technology.Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopyMagnetic resonance chemical exchange saturation transfer imaging and nanotechnology.Post-formulation peptide drug loading of nanostructures for metered control of NF-κB signalingNanoparticles for biomedical imagingAntithrombin nanoparticles improve kidney reperfusion and protect kidney function after ischemia-reperfusion injury.Balanced UTE-SSFP for 19F MR imaging of complex spectraHigh vapor pressure perfluorocarbons cause vesicle fusion and changes in membrane packing.Two-color fluorescent (near-infrared and visible) triphasic perfluorocarbon nanoemuslions.Copper-64 Radiopharmaceuticals for Oncologic ImagingCombining nanotechnology with current biomedical knowledge for the vascular imaging and treatment of atherosclerosis.Using fluorochemical as oxygen carrier to enhance the growth of marine microalga Nannochloropsis oculata.
P2860
Q27025491-FB7A113D-4C19-45AE-8964-FCC994BA83D8Q28486071-BE29DEC5-C5EC-44C0-A54F-9458A3DC476EQ30426880-48DC0D7F-5DD4-4D5D-B875-893D91F2F045Q30434964-9E6C19AF-8062-4365-B02C-BCFB2793DB58Q30450131-35F1FBFE-5189-4063-903D-FE75CF8E0BC1Q30465710-F045A9E7-455A-47FA-9A31-1C57CCCCEA8DQ30466278-6D30D7AA-3036-4876-9740-91CDA5AEE0A5Q30477993-BCAA44C5-28F5-487C-986A-CF0586CE3822Q30488702-29A2360C-A937-4C40-AA97-155E68D526F6Q34197669-96AA0D41-3DF9-4DCE-BB8F-16F11011DCFFQ34381627-24A87830-2E24-4072-921F-CBCBBA5F1B77Q34989401-3FB42445-44E6-4BE0-8208-8B3F0E046E33Q35274033-C3E05F60-81A6-4423-BAB8-7FAA361E43C7Q35789062-4B429D1A-388A-47A0-A420-F8FB421E0B9FQ36957316-CBE8AB63-7F9B-4440-8456-ECB66C0FB637Q37064676-83462A9C-91A9-4E27-90BD-B02DBA4861DEQ37126530-7031C1C4-94CB-4045-BE42-B00C5EA4B6B4Q37696318-DAB54C43-2D62-4B6F-9E2F-CEFA44BABD3CQ46805024-EEC47DB2-6201-40BE-ACA9-8BB02EE9FAD7
P2860
Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.
@ast
Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.
@en
type
label
Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.
@ast
Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.
@en
prefLabel
Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.
@ast
Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.
@en
P2093
P2860
P356
P1476
Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.
@en
P2093
Gregory M Lanza
Samuel A Wickline
Shelton D Caruthers
P2860
P304
P356
10.1586/17434440.4.2.137
P577
2007-03-01T00:00:00Z